Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Kiwi (Actinidia deliciosa) has been investigated in several studies for its potential role in supporting cardiovascular health and, specifically, for its effects on platelet aggregation and blood clotting. Some small clinical trials have shown that regular consumption of kiwi fruit can reduce platelet aggregation and lower blood triglyceride levels, both of which are factors involved in the development of blood clots and cardiovascular disease. For instance, a study published in 2004 in "Platelets" found that eating two to three kiwis per day for 28 days significantly reduced platelet aggregation and plasma triglycerides in healthy volunteers, suggesting a mild antithrombotic effect. The proposed mechanisms include the presence of polyphenols, vitamin C, and other bioactive compounds in kiwi that may modulate platelet function and vascular health.

However, the evidence base is still limited, with relatively few human studies and modest sample sizes. No large-scale randomized controlled trials have established kiwi as a primary or adjunctive therapy for preventing blood clots. Thus, while there is some scientific validation for kiwi’s potential to mildly reduce clotting risk, the current evidence is preliminary and does not support its use as a replacement for established anticoagulant therapies. Kiwi may be considered a supportive dietary measure for cardiovascular health, but further research is needed to confirm its efficacy and safety in this context.

More about Kiwi
More about Blood Clots (prevention of)

Other ingredients used for Blood Clots (prevention of)

Other health conditions supported by Kiwi

Products containing Kiwi